共 42 条
[1]
Fong DS(2004)Diabetic retinopathy Diabetes Care 27 2540-2553
[2]
Aiello LP(2007)Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema Dev Ophthalmol 39 69-87
[3]
Ferris FL(1998)Vitrectomy in diabetic retinopathy: outcome, risk factors, complications Klin Monatsbl Augenheilkd (Written In German) 212 339-342
[4]
Klein R(2007)Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer J Clin Pharm Ther 32 1-14
[5]
Joussen AM(2006)Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 1695.e1-1695.e15
[6]
Joeres S(2006)Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy Retina 26 699-700
[7]
Helbig H(2006)Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy Am J Ophthalmol 142 685-688
[8]
Kellner U(2006)Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema Retina 26 999-1005
[9]
Bornfeld N(1953)Ocular complications of diabetes mellitus Br J Ophthalmol 37 705-715
[10]
Foerster MH(2006)Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients Retina 26 871-876